Borsellino Beatrice, Savi Arianna, Pascale Maria Rosaria, Meddi Elisa, Del Principe Maria Ilaria, Cristiano Antonio, Ottone Tiziana, Rapanotti Maria Cristina, Divona Mariadomenica, Travaglini Serena, Attardi Enrico, Palmieri Raffaele, Buzzatti Elisa, Buccisano Francesco, Voso Maria Teresa
Department of Biomedicine and Prevention, University of Tor Vergata, Rome, Italy.
Hematology Clinic, Department of Clinical and Molecular Sciences, DISCLIMO, AOU Ospedali Riuniti-Università Politecnica delle Marche, Ancona, Italy.
Mediterr J Hematol Infect Dis. 2022 Jul 1;14(1):e2022058. doi: 10.4084/MJHID.2022.058. eCollection 2022.
The evolution of myeloproliferative neoplasms (MPN) to acute myeloid leukemia (AML) occurs in 2-10% of patients, depending on the MPN subtype, treatment, and follow-up length. The reverse-path from AML to MPN has been rarely reported. We herein present a 75 years old woman with AML, in whom a -V617F positive polycythemia vera (PV) emerged during follow-up, 19 months from the end of consolidation treatment. V617F mutation screening retrospectively performed by Next Generation Sequencing (NGS) and MutaScreen was negative on the bone marrow sample collected at AML diagnosis. However, using digital droplet PCR (ddPCR), we detected a minor V617F mutated clone at AML onset. In addition, a TET2 R550 mutated clone persisted at stable levels throughout the disease course. This case shows that a very small MPN clone masked at AML diagnosis may expand after treatment end and be erroneously interpreted as MPN evolving from AML. Very sensitive techniques such as ddPCR may help to unravel the true disease history in these cases.
骨髓增殖性肿瘤(MPN)演变为急性髓系白血病(AML)的情况在2%-10%的患者中发生,这取决于MPN的亚型、治疗以及随访时间的长短。从AML逆向发展为MPN的情况鲜有报道。我们在此报告一例75岁患有AML的女性患者,在巩固治疗结束19个月后的随访期间出现了JAK2-V617F阳性真性红细胞增多症(PV)。通过下一代测序(NGS)和MutaScreen对AML诊断时采集的骨髓样本进行回顾性V617F突变筛查,结果为阴性。然而,使用数字液滴PCR(ddPCR),我们在AML发病时检测到一个微小的V617F突变克隆。此外,一个TET2 R550突变克隆在整个病程中持续处于稳定水平。该病例表明,在AML诊断时被掩盖的一个非常小的MPN克隆在治疗结束后可能会扩大,并被错误地解释为MPN由AML演变而来。像ddPCR这样非常灵敏的技术可能有助于在这些病例中揭示真实的疾病史。